NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
3.490
+0.050 (1.45%)
Jul 28, 2026, 4:00 PM EDT - Market closed
NTHI Revenue
In the year 2025, NeOnc Technologies Holdings had annual revenue of $39.99K, down -51.82%.
Revenue (ttm)
$39.99K
Revenue Growth
-51.82%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
90.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.99K | -43.01K | -51.82% |
| Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
| Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
| Dec 31, 2022 | 20.00K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Verrica Pharmaceuticals | 37.16M |
| Pelthos Therapeutics | 27.70M |
| Coya Therapeutics | 7.94M |
| Rallybio | 858.00K |
NTHI News
- 1 day ago - NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors - GlobeNewsWire
- 13 days ago - NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition - GlobeNewsWire
- 27 days ago - Wall Street is Watching These Biotechs - GlobeNewsWire
- 4 weeks ago - NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum - GlobeNewsWire
- 5 weeks ago - NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone - GlobeNewsWire
- 5 weeks ago - NeOnc Technologies Holdings Proxy statement: Proxy filing - Filings
- 5 weeks ago - NeOnc Technologies Holdings Proxy statement: Proxy filing - Filings
- 5 weeks ago - WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy - Newsfile Corp